×
Import Page Template
Please Wait a Moment
About
What We Stand For
CTS History
Board Of Directors
Senior Leadership
Services
Donor Testing
Plasma Testing
Research & Development
Resources
Accreditation/ Licenses
Assays
At A Glance
News
Articles
Communications
Presentations
Videos
Contact Us
Lab Addresses
Client Services
Media Inquiries
General Contact
Careers
CTS Connect Login
|
X
About
What We Stand For
CTS History
Board Of Directors
Senior Leadership
Services
Donor Testing
Plasma Testing
Research & Development
Resources
Accreditation/ Licenses
Assays
At A Glance
News
Articles
Communications
Presentations
Videos
Contact Us
Lab Addresses
Client Services
Media Inquiries
General Contact
Careers
CTS Connect Login
Articles
News
Articles
Articles
Communications
Presentations
Videos
02
Jan
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
SuperUser Account
|
02 Jan, 2024
|
IPFA welcomes Marion Lanteri as Executive Board member, CTS as new member organization
30
May
VP, Scientific Affairs Dr. Marion Lanteri Speaks at Symposium on Alternatives to Donation Deferral
Courtney Griggs
|
30 May, 2023
|
As an organization dedicated to the safety of the world’s blood and plasma supply, Creative Testing Solutions’ Research & Development team and its research collaborators contribute to studies monitoring emerging and ongoing safety concerns in blood and biologics. For example, CTS continues to provide critical data regarding the safety of the blood supply after donor deferrals for Men who have Sex with Men (MSM) changed in the last few years. Based on this data and the collective international ...
08
Sep
Dr. Marion Lanteri Joins Creative Testing Solutions as Scientific Affairs VP
O'Dina Hurlburt
|
08 Sep, 2022
|
TEMPE, Ariz. (Sept. 8, 2022) — Marion Lanteri, Ph.D., began this week as Creative Testing Solutions’ vice president of scientific affairs. CTS is a leading research partner, tracking infectious disease markers in the national blood supply, among many other significant projects. As the largest nonprofit blood and plasma laboratory organization in the world, CTS exists to ensure the safety of blood and plasma-derived products for life-saving transfusion and therapeutic use.Lanteri will...
04
Jan
FDA Updates Emergency Use Authorization for COVID-19 Convalescent Plasma
Lindsey Houghton
|
04 Jan, 2022
|
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 convalescent plasma. The update limits the authorization to the use of COVID-19 convalescent plasma with high titers of anti -SARS-CoV-2 antibodies for the treatment of COVID-19 in patients with immunosuppressive disease or who are receiving immunosuppressive treatment. Additionally, to help assure the manufacture of high titer COVID-19 convalescent plasma, the revisions to the EUA define a...
03
Jan
National Blood Donor Month
O'Dina Hurlburt
|
03 Jan, 2022
|
National Blood Donor Month has been observed in January since 1970, with the goal of increasing blood and platelet donations during the winter. One of the most difficult times of the year to collect enough blood products to meet patient needs. Extreme winter weather often results in canceled blood drives, and seasonal illnesses like flu and/or COVID-19 may cause donors to become temporarily unable to donate.
17
Dec
Creative Testing Solutions and Grifols Forge New Testing Partnership
Courtney Griggs
|
17 Dec, 2021
|
Creative Testing Solutions, the largest nonprofit blood testing organization in the U.S., today announced a new partnership with Grifols. On April 1, 2022, Creative Testing Solutions will assume responsibility for operations of Grifols’ three testing facilities in San Marcos, TX, Austin, TX, and Memphis, TN.
19
Jul
Sample submission during the national blood shortage
Lindsey Houghton
|
19 Jul, 2021
|
Through communications with our clients, CTS is aware of the current national blood shortage. We realize this situation makes it even more critical that we report your results on time. While most test result reporting delays are CTS’ responsibility, there are ways you can help reduce delays.We have noted that some test result delays are associated with an inadequate donor sample set. The two primary causes are when only two tubes instead of three are submitted for routine donations or when...
12
May
FDA announces withdrawal of Guidance for ZIKV Testing
Lindsey Houghton
|
12 May, 2021
|
We are informing you that the FDA has announced their withdrawal of Guidance for ZIKV Testing. In their announcement, FDA indicated the Zika virus (ZIKV) is no longer a relevant transfusion-transmitted infection (RTTI) under FDA’s regulations, and the available evidence demonstrates that ZIKV no longer has sufficient incidence and/or prevalence to affect the potential donor population. Accordingly, the guidance titled, “Revised Recommendations for Reducing the Risk of Zika Viru...
25
Jan
CTS implements Ortho VIP Viral Marker Testing Platform
O'Dina Hurlburt
|
25 Jan, 2021
|
On January 25, 2021, CTS implements the Ortho VIP viral marker testing platform. Conversion from the Prism to the VIP is one of the most significant changes we have made in the past three years. We implemented the new system through the dedication and extraordinary effort of everyone across the enterprise. Congratulations on this important success!
11
Jan
Reminder-Revised Client Forms
O'Dina Hurlburt
|
11 Jan, 2021
|
Just a reminder that the revised client forms implement today! Don't forget to toss your old versions! If you need a refresher on what forms are impacted, you can read about it here:
Communications
Page 1 of 10
First
Previous
[1]
2
3
4
5
Next
Last